阿尔茨海默病中的微质功能障碍:机制,新兴疗法和未来的方向
Mahir Azmal1, Jibon Kumar Paul1, Fatema Sultana Prima1
1Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet 3114, Bangladesh.
Experimental neurology
|July 12, 2025
概括
微质细胞,大脑的免疫细胞,在阿尔茨海默病 (AD) 中从保护性转变为有害的作用. 针对它们的炎症途径为AD治疗提供了新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 涉及粉样β (Aβ) 斑块,团,以及神经炎症.
- 微质细胞,大脑的免疫细胞,是AD病原体的核心.
- 微质功能障碍从神经保护过渡到有害的炎症.
研究的目的:
- 探索AD中微质功能障碍的分子机制.
- 为了强调关键的炎症途径 (NF-κB,MAPK,TLR4) 驱动神经炎症.
- 检查针对微质活动的治疗策略.
主要方法:
- 在微质功能障碍中的分子机制的审查.
- 对炎症信号通路 (NF-κB,MAPK,TLR4) 的分析.
- 对阿尔茨海默病新出现的治疗策略的检查.
主要成果:
- 长时间的微质激活促进了促炎状态.
- 炎症途径释放细胞因子 (IL-1β,TNF-α,IL-6),加剧神经炎症.
- 遗传 (APOE4) 和环境因素调节微质活动.
结论:
- 调节微质活动是阿尔茨海默病的一个有前途的治疗策略.
- 纵向研究对于了解微质在疾病进展中的作用至关重要.
- 个性化医疗方法对于有效的AD治疗至关重要.
相关概念视频
01:26Alzheimer's Disease: Overview
673
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
673
01:22Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263